Home Blog Page 809

Singapore Management University Graduates Remain Resilient in Cautious Job Market; 91.4% Secured Employment

SINGAPORE, March 9, 2026 /PRNewswire/ — Graduates from Singapore Management University continue to secure good employment outcomes despite a more cautious hiring climate, with more than nine in ten securing employment within six months of graduation, according to the latest Joint Autonomous University Graduate Employment Survey (JAUGES) 2025.

The results suggest sustained employer demand for graduates with industry exposure and applied skills, even as organisations become more cautious amid global economic uncertainty and accelerating automation.

Strong Employment Outcomes in a More Cautious Hiring Environment

SMU graduates remain in demand and continue to demonstrate resilience in a moderated hiring environment. The results were revealed in the annual JAUGES, jointly conducted by SMU and the other Autonomous Universities. Of SMU’s 2,331 graduates in the Class of 2025, 1,710 responded to the survey, representing a 73.4% response rate.

Under the newly introduced secured employment rate indicator – which includes graduates who have accepted a job offer but have yet to commence work, as well as those starting their own ventures – SMU recorded a strong 91.4% secured employment rate, with an overall employment rate of 87.1% and a full-time permanent employment rate of 79.8%.

SMU graduates are also commanding good wages, with the average gross monthly salary rising to $5,116 from $5,057 the previous year, while the median gross salary of our graduates also increased to $4,747 from $4,600. See Annex A for more details.

Nearly Half Received Full-Time Offers Through Internships

A hallmark of SMU’s distinctive education model is its mandatory internship programme. Of graduates in full-time permanent employment,

  • 30.9% of full-time permanently employed graduates are working or have worked in the same company where they interned.
  • 16.4% reported being offered positions by their host companies but chose not to take up the offer.

Taken together, this indicates that nearly half of SMU graduates were offered full-time permanent employment during or after their penultimate-year internship, a strong endorsement of employer confidence in SMU talent.

SMU’s structured, mandatory internship framework contributes rigour and workplace relevance to students’ applied learning and plays a decisive role in preparing them not just for their first job, but for sustained career success.

Strong Demand Across Professional Sectors

As with previous GES findings, industries such as Finance and Insurance, Legal, Accounting & Auditing, and Information & Communication remained top employment sectors, reflecting sustained employer demand that is aligned with SMU’s disciplinary strengths. 61.4% of full-time permanently employed graduates received employment offers before graduation – a 1.3 percentage point increase compared to the 2024 cohort.

Career Services Remain Available to SMU Graduates

SMU’s Dato’ Kho Hui Meng Career Centre (DKHMCC) will continue to offer lifelong career support to all alumni of our undergraduate and postgraduate programmes, with continued access to a 24/7 jobs portal, and personalised assistance by individual career coaches.

Preparing Graduates for a Rapidly Changing Economy

SMU Provost and Kwan Im Thong Hood Cho Temple Chair Professor of Inter-Religious Studies and Harmony, Professor Alan Chan, remarked: “While hiring conditions are becoming more cautious as organisations manage uncertainty and accelerate automation, this is precisely where SMU’s learning model proves its strength. We are intensifying our efforts to equip our students with essential human-centred competencies, such as strong critical thinking and communication skills as well as a high degree of AI fluency, which are vital to flourishing in a rapidly changing work environment. We will further enhance experiential and interactive learning that is the hallmark of an SMU education.”

SMU’s high employment rates stem from its distinctive experiential learning model, which integrates academia with real-world application. SMU’s mandatory internship programme along with the SMU-X programme and Work Study Electives connect students with industry leaders to tackle live business challenges, while community service and global exposure requirements ensure graduates develop adaptability, cross-cultural fluency, and a sense of social responsibility – attributes highly valued in today’s evolving job market.

Professor Alan Chan added, “More internship and global education opportunities will be provided, with a sharpened focus on preparing students to be Asia-ready and future-ready. Our goal is to ensure SMU graduates remain resilient, adaptable, and highly competitive, not just for today’s roles, but for the evolving careers of tomorrow.”

As Singapore’s economy evolves, the university is strengthening partnerships with industry to ensure graduates develop the applied skills, digital capabilities and adaptability required in an increasingly technology-driven labour market.

About SMU’s Dato’ Kho Hui Meng Career Centre (DKHMCC)

DKHMCC offers a range of comprehensive services, programmes, and resources for SMU students to chart their career directions and empowers them with the necessary skills to realise their potential and goals.

Each student is assigned a career coach upon matriculation to support them in career planning through his/her four-year journey at SMU. These certified coaches from DKHMCC come from diverse backgrounds and are in tune with industry developments and trends. They administer personality/career profiling tools, critique cover letters and resumes, facilitate job searches, and hone students’ interview skills.

In addition, DKHMCC offers a suite of internship readiness modules and career readiness workshops from the freshman year as part of SMU’s pioneering Finishing Touch programme. The programme equips SMU undergraduates with career planning and transferable skills, geared towards enhancing their employment prospects and fulfilling their career goals progressively throughout the four-year course of study. Every year, DKHMCC organises more than 400 events, including career and industry talks, employability clinics, career fairs, as well as networking events for our students.

Recognising the importance and value of having real-world and career-relevant work experience for its students, SMU is the first university in Singapore to make internships compulsory for all students. Students are provided opportunities via DKHMCC, which works closely with industry to ensure successful placements in internships and jobs. The DKHMCC’s close and regular contact with employers is vital in helping SMU students be market-relevant and career-ready. Students also have access to a 24/7 web-based portal (OnTRAC) to search for internships and career opportunities.

DKHMCC also offers lifelong career support to all alumni of our undergraduate and postgraduate programmes, with continued access to the jobs portal, and personalised assistance by individual career coaches, should they require further guidance.

About SMU

A premier university in Asia, SMU is internationally recognised for its world-class research and distinguished teaching. Established in 2000, SMU’s mission is to generate leading-edge research with global impact and to produce broad-based, creative, and entrepreneurial leaders for the knowledge-based economy. SMU’s education is known for its highly interactive, collaborative, and project-based approach to learning.

Home to over 13,000 students across undergraduate, postgraduate professional and postgraduate research programmes, SMU comprises eight schools: School of Accountancy, Lee Kong Chian School of Business, School of Economics, School of Computing and Information Systems, Yong Pung How School of Law, School of Social Sciences, College of Integrative Studies, and College of Graduate Research Studies. SMU offers a wide range of bachelors’, masters’, and PhD degree programmes in the disciplinary areas associated with its schools, as well as in multidisciplinary combinations of these areas.

SMU emphasises rigorous, high-impact, multi- and interdisciplinary research that addresses Asian issues of global relevance. SMU faculty members collaborate with leading international researchers and universities around the world, as well as with partners in the business community and public sector. SMU’s city campus is a modern facility located in the heart of downtown Singapore, fostering strategic linkages with business, government, and the wider community. www.smu.edu.sg

SMU celebrates its 25 years of meaningful impact this year, and remains committed to its vision of driving innovation, transcending boundaries and transforming lives.

ANNEX A

SMU’s 2025 graduates across all eight University degree programmes enjoyed competitive monthly salaries

Computer Science graduates earn a mean gross monthly salary of $6,135. The median gross monthly salary is $6,000, unchanged from 2024. Those with Cum Laude or better earned a mean gross monthly salary of $6,513 and a median gross monthly salary of $6,250.

Information Systems graduates earn a mean gross monthly salary of $5,515 as compared to the 2024 cohort’s $5,362. The median gross monthly salary is $5,400 a significant improvement from $5,000 in 2024. Those with Cum Laude or better earned a mean gross monthly salary of $5,919 and a median gross monthly salary of $5,785.

Economics graduates earn a mean gross monthly salary of $4,900. The median gross monthly salary is $4,500. Those with Cum Laude or better earned a mean gross monthly salary of $5,247, while the median gross monthly salary is $5,000.  

Business Management graduates earn a mean gross monthly salary of $5,234, a slight increase from last year’s $5,007. The median gross monthly salary is $4,600 up from $4,500 in 2024. Those with Cum Laude or better earned a higher mean gross monthly salary of $5,618, an increase from last year’s $5,323, while the median gross monthly salary is $5,000.

Accountancy graduates earn a mean gross monthly salary of $4,774 as compared to $4,755 in 2024. The median gross monthly salary is $4,350, unchanged from 2024. Those with Cum Laude or better earned a mean gross monthly salary of $5,130 while the median gross monthly salary was $4,500.

Social Sciences graduates earn a mean gross monthly salary of $4,247. The median gross monthly salary is $4,000. Those with Cum Laude or better earned a mean gross monthly salary of $4,489. The median gross monthly salary is $4,350.

Please refer to Annex B for the detailed figures.

Annex B: https://mma.prnewswire.com/media/2929153/Annex_B_Web_Publication_SMU_GES_2025.pdf

Explanatory Note: Cum Laude and Merit Awards

SMU uses the cumulative Grade Point Average (GPA) criteria to identify degree candidates with academic excellence in the following award categories: Summa Cum Laude, Magna Cum Laude and Cum Laude. These are Latin awards adopted from the American system, and can be translated as with Highest Distinction, with High Distinction and with Distinction, respectively.

They do not equate to the various classes of degree honours conferred by universities that follow the British system of academic honours. A graduate needs a GPA of at least 3.40 out of 4.00 to be awarded Cum Laude. All SMU bachelor’s degrees are four-year full-time programmes.

Cumulative GPA

Awards

≥ 3.80

Summa Cum Laude

3.60 to 3.79

Magna Cum Laude

3.40 to 3.59

Cum Laude

3.20 to 3.39

High Merit

3.00 to 3.19

Merit

 

Guangdong aims to shoulder greater responsibilities at the beginning of the 15th Five-Year Plan period

GUANGZHOU, China, March 9, 2026 /PRNewswire/ — On the afternoon of March 6, 2026, the Guangdong provincial delegation held an open meeting during the Fourth Session of the 14th National People’s Congress in Beijing. The event drew 277 journalists from 111 media outlets, including 61 foreign organizations. Reporters asked questions actively; delegates answering included Huang Kunming, Secretary of the CPC Guangdong Committee, and Meng Fanli, Governor of Guangdong. The meeting was chaired by Huang Chuping, Chairman of the Standing Committee of the Guangdong Provincial People’s Congress.

Guangdong_Province_meeting
Guangdong_Province_meeting

A Xinhua News Agency reporter noted that during his inspection of Guangdong in November 2025, Chinese President Xi Jinping gave guidance for the province’s scientific planning for the 15th Five-Year Plan period, encouraging Guangdong to take the national lead, set an example for the country, and shoulder greater responsibilities. The reporter asked about Guangdong’s implementation plans. Huang Kunming outlined the province’s vision and key priorities for the year in four areas: “strengthening the two cornerstones of industry and technology,” “advancing reform and opening up while adhering to the mass line,” “expanding into county-level areas and the maritime domain,” and “energizing the two main drivers of enterprises and talent.”

Huang Kunming said Guangdong has vigorously promoted the mutual reinforcement of industry and technology in recent years, leading to the province’s top ranking in regional innovation capability for nine consecutive years. The nine mainland cities in the Guangdong‑Hong Kong‑Macao Greater Bay Area saw foreign trade imports and exports rise 4.4% despite headwinds, and actual use of foreign capital increase 11.3%. ‘Guangdong‑made products’ perform strongly across China and overseas, injecting momentum into the province’s high‑quality development. As Guangdong begins the crucial stage of the 15th Five‑Year Plan period, it aims to cultivate more industrial clusters worth hundreds of billions or trillions of yuan in emerging fields such as 6G, the low‑altitude economy, embodied artificial intelligence, and quantum technology. Huang Kunming extended a warm invitation to media professionals to visit Guangdong, explore its strengths, enjoy its cuisine, and experience the charm of the Lingnan region.

Huang Kunming proactively invited journalists from Macau to ask questions. A reporter from Macau Global Chinese Business News asked what message he had for the Macau press. Huang Kunming said that after years of close collaboration with Macau, both the “hardware and software” foundations have become increasingly mature. Guangdong offers numerous advantages, significant opportunities, and broad space for growth. He welcomed insightful people from all sectors in Macau—especially young people—to come to Hengqin to start or expand businesses or to work.

Responding to a question from a China Media Group reporter, Governor Meng Fanli noted that Guangdong has the largest manufacturing sector in China. During the 15th Five‑Year Plan period, Guangdong will prioritize accelerating high‑quality development of the service sector as a key task in advancing industrial and economic upgrading. The focus will be on “advancing six key dimensions and fostering a robust industrial ecosystem.” The six dimensions are integration, high‑end advancement, digital intelligence, green development, internationalization, and diversification. At the same time, the province will cultivate an industrial ecosystem that supports healthy, rapid growth in services, increase investment in service industries, and build world‑class industrial parks alongside diverse online and offline platforms and carriers.

At the 1.5‑hour interactive session, journalists repeatedly raised questions on hot topics about Guangdong’s development. Delegates responded directly and candidly, sharing their experiences in office and outlining future plans, conveying determination and confidence in advancing during the 15th Five‑Year Plan from multiple perspectives.

TelkomMetra Streamlines Business Portfolio, AdMedika Group Poised to Enter a New Growth Phase on Regional Level Under Fullerton Health

A Strategic divestment steps to strengthen the fundamentals of TelkomGroup as the main holding and focus on the core business of digital and telecommunications

JAKARTA, Indonesia, March 9, 2026 /PRNewswire/ — PT Multimedia Nusantara (TelkomMetra), as one of the subsidiaries of PT Telkom Indonesia (Persero) Tbk (Telkom) (together, the TelkomGroup) has officially signed a Conditional Share Purchase Agreement (CSPA) marking a critical and strategic step toward the full divestment of PT Administrasi Medika (AdMedika), including its subsidiary TelkoMedika (together, the AdMedika Group), to the Fullerton Health group of companies (Fullerton Health). This move is aligned with the state-owned enterprise (SOE) streamlining agenda mandated by Danantara to TelkomGroup, which has become one of the focus areas of the TLKM 30 transformation program. As part of the implementation of TelkomGroup’s transformation strategy, this portfolio restructuring and streamlining effort aims to strengthen focus on Telkom Group’s core business in the telecommunications and digital sectors, while opening new business opportunities for AdMedika Group to expand nationally and into the regional market.

AdMedika Group has entered a new growth phase following the signing of a Conditional Share Purchase Agreement (CSPA) between TelkomMetra and Fullerton Health.
AdMedika Group has entered a new growth phase following the signing of a Conditional Share Purchase Agreement (CSPA) between TelkomMetra and Fullerton Health.

AdMedika Group, a company that provides technology-based health administration services (third party administrator/TPA), has established a strong track record in providing claims management solutions and healthcare services to corporations and institutions in Indonesia. Amid increasingly competitive dynamics in the healthcare and insurance industries, AdMedika Group’s sustainability and accelerated development are considered to be better supported by a strategic shareholder whose business is aligned with AdMedika Group’s operations.

President Director of TelkomMetra, Pramasaleh Haryo Utomo, stated, “The signing of the CSPA with Fullerton Health, which marks a step toward the full divestment of AdMedika Group, is a carefully measured decision made by upholding the principles of Good Corporate Governance, based on comprehensive business considerations, and aligned with TelkomGroup’s transformation to strengthen its focus on the core business and to create long-term value.”

The CSPA between TelkomMetra as seller and Fullerton Health as buyer was signed on 4 March 2026.

“This acquisition reflects Fullerton Health’s commitment to strengthening our presence and contribution to Indonesia’s healthcare landscape. AdMedika Group has been thoughtfully developed within the TelkomGroup into a trusted and highly comprehensive healthcare administration platform, built on strong governance, digital innovation and clinical discipline. These qualities closely align with our own capabilities and values. We see this acquisition as an important step toward expanding access to high quality healthcare for the people of Indonesia and across the region,” said Ho Kuen Loon, Group of CEO Fullerton Health.

“This creates an opportunity to enhance service delivery and better meet the evolving needs of patients, clients and partners across the country.”

Fullerton Health, which shall be the new owner of AdMedika Group upon completion of the acquisition pursuant to the CSPA, brings deep regional experience and proven operational capabilities across Asia’s healthcare and benefits landscape. The combined strengths of both organisations create a broader platform for growth, pairing the AdMedika Group’s strong local foundation with Fullerton Health’s regional expertise in managed care, healthcare provider networks and digital health. This positions the expanded platform to scale more effectively, advance innovation, and reinforce AdMedika’s leadership in TPA solutions in Indonesia, while opening pathways for future expansion across the wider region.

About AdMedika Group

AdMedika Group, acquired by TelkomGroup through TelkomMetra in 2010, is a third party administrator (TPA) company with the largest network in Indonesia, providing claims management solutions, provider network management, and integrated digital health services for corporations, insurance companies, and institutions. As part of the national healthcare ecosystem, AdMedika combines technological excellence with proven operational capabilities to deliver fast, accurate, and transparent services to customers. For more information, visit https://www.admedika.co.id/.

About Fullerton Health

Established in 2010, Fullerton Health is a leading integrated healthcare solutions provider in Asia Pacific. Operating across nine markets, the Group runs approximately 550 healthcare facilities and partners with more than 20,000 providers, delivering end-to-end services spanning managed care, primary care, diagnostics, speciality services and ancillary solutions.

Supported by a workforce of almost 8,000 employees, Fullerton Health serves over 26,000 corporate clients and facilitates beyond 14 million healthcare transactions annually, impacting more than 4 million lives across the region.

Combining clinical excellence, corporate healthcare expertise and digital innovation, Fullerton Health is committed to delivering seamless, accessible and trusted healthcare for all. For more information, visit https://www.fullertonhealth.com/.

AdMedika customer service officers provide technology-based healthcare administration support, delivering fast and reliable claims management solutions to corporate and institutional clients across Indonesia.
AdMedika customer service officers provide technology-based healthcare administration support, delivering fast and reliable claims management solutions to corporate and institutional clients across Indonesia.

An AdMedika medical professional supports the operations team to ensure accurate and high-quality healthcare administration services
An AdMedika medical professional supports the operations team to ensure accurate and high-quality healthcare administration services

PELA Executes US$5 Million U.S. Government Project Development Funding Agreement

PERTH, Australia, March 9, 2026 /PRNewswire/ — Pela Global Limited (“PELA” or “the Company”) is pleased to announce that, following a rigorous application and approval process, the Company has executed a Project Development Funding Agreement (Agreement) with the U.S. International Development Finance Corporation (DFC). The Agreement provides up to US$5 million in project development funding to support and advance PELA’s flagship Krstov Dol Antimony Mine Restart Project (KDM) in North Macedonia.

The funding represents a significant milestone in PELA’s strategy to become a near-term supplier of critical minerals to allied markets. The Agreement provides funding support for defined project development activities at KDM, including the preparation of a Mineral Resource Estimate to be reported in accordance with the JORC Code, completion of an Environmental and Social Impact Assessment, and progression of the project toward feasibility.

The project is underpinned by historical mining activity and a substantial body of historical geological and technical data, including historical mineral resource and reserve estimates prepared and approved under the former Yugoslav reporting system.

About Pela Global Limited

Pela Global Limited is an Australian critical and precious metals company focused on the responsible development of mineral resources across Southeastern Europe’s Tethyan Metallogenic Belt. Its key assets include:

  • Krstov Dol Antimony Project (North Macedonia) – An advanced-stage project aiming to produce high-grade antimony concentrate from a historically producing site, strategically positioned to support Western critical minerals supply objectives.
  • Samar Gold Project (North Macedonia) – A high-grade polymetallic system with confirmed gold, silver, lead, zinc, and copper mineralisation, offering strong exploration and development potential.

Pela’s board of directors is pleased to advise that it is currently considering the opportunity to undertake an initial public offering of its shares (IPO) in support of an application for admission to an Australian securities exchange.

If the board determines to proceed with an IPO, Pela will make available a prospectus with the full terms and other details of the IPO. While there is no guarantee that the IPO will necessarily proceed, the Company will look to provide updates in this regard on its website and/or by email.

For more information, visit www.pelaglobal.com.

Everest Medicines Announces Commercial Launch and First Prescription for VELSIPITY® in Mainland China

SHANGHAI, March 9, 2026 /PRNewswire/ — Everest Medicines (HKEX 1952.HK, “Everest”, or the “Company”), a biopharmaceutical company focused on the discovery, clinical development, manufacturing and commercialization of innovative therapeutics, today announced the commercial launch of VELSIPITY® (etrasimod arginine tablets) in Mainland China, highlighted by the issuance of the first prescription at The First Affiliated Hospital of Sun Yat-sen University, marking a milestone in patient access in the region. As a once-daily oral therapy with sustained efficacy, a favorable safety profile, and the ability to achieve deep mucosal healing, VELSIPITY® offers a novel treatment option for patients with moderately to severely active ulcerative colitis (UC), supporting long-term disease control and improved outcomes.

VELSIPITY® is a next-generation, highly selective S1P receptor modulator with best-in-disease potential and strong first-line treatment recommendations in leading international guidelines. China’s National Medical Products Administration (NMPA) has approved VELSIPITY® on February 2, 2026, for the treatment of adult patients with moderately to severely active ulcerative colitis (UC) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent.

“With the first prescription now issued, VELSIPITY® is being incorporated into routine clinical practice, providing physicians with an innovative treatment option for patients living with UC who continue to face ongoing disease challenges, ” said Prof. Chen Minhu, Academic Leader of the Department of Gastroenterology at The First Affiliated Hospital of Sun Yat-sen University. “Results from multiple global clinical studies have demonstrated that VELSIPITY® delivers meaningful clinical benefits, including rapid onset of action, long-lasting clinical remission, steroid-free remission, and deep mucosal healing, with a favorable safety profile. In the ENLIGHT UC study, the largest Asian multicenter Phase 3 clinical study, the clinical remission rate at week 40 of the maintenance period reached 48.1%, and the deep mucosal healing rate reached 51.9%, with an endoscopic mucosal normalization rate of 45.5%[1]. These findings demonstrate VELSIPITY®‘s potential to improve long-term disease outcomes and reduce the risk of relapse and disease progression.

Results from the ELEVATE UC open-label extension demonstrate continuous treatment with VELSIPITY® for up to 3 years resulted in 86.8% of patients achieving a clinical response among the observed cases, with both clinical remission and mucosal healing rates maintained at approximately 60%[2]. Safety data extending up to five years from the global clinical program further confirm that VELSIPITY® is well tolerated and maintains a favorable and stable safety profile[3].

Under the ‘Hong Kong and Macao Drug and Medical Devices Transit’ policy, VELSIPITY® has been introduced into clinical use in the Greater Bay Area, where real-world outcomes have demonstrated efficacy and safety consistent with those observed in clinical trials. We expect VELSIPITY® to play an important role in optimizing UC management and advancing treatment toward the goal of mucosal healing, benefiting more patients.”

Ulcerative colitis is a chronic, relapsing, non-specific inflammatory bowel disease characterized by symptoms such as mucus and blood in the stool, abdominal pain, diarrhea, and rectal tenesmus, which can significantly impact patients’ daily lives and long-term health. In China, both the incidence and prevalence of UC are increasing, with a clear trend toward younger patients. There remains a critical need for therapies that offer sustained and comprehensive disease control.

“We are pleased to see that VELSIPITY® achieved its first prescription in Mainland China just one month after approval, making this potentially best-in-disease therapy clinically available to a broader population of patients living with UC. This milestone underscores our ability to efficiently translate cutting-edge global therapies into clinical practice,” said Mr. Rogers Yongqing Luo, Chief Executive Officer of Everest Medicines. “UC is an incurable disease, and the patient population is projected to grow from approximately 0.98 million in 2025 to 1.50 million by 2031 in China[4],[5]. Patients require long-term management to maintain disease control.

Early achievement of mucosal healing is recognized as a key treatment goal, as it can significantly reduce rates of disease relapse, hospitalization, surgery, and the risk of progression to colorectal cancer. VELSIPITY® addresses this need by targeting intestinal inflammation at its source and promoting mucosal healing, while offering a favorable profile of efficacy and safety, along with the convenience of an oral, once-daily regimen, supporting sustained disease management and improving patients’ quality of life.

Everest has built a proven platform for the commercialization of innovative medicines, integrating scientific and commercial insights with coordinated access, medical, marketing, and sales (A2MS). We are confident in accelerating the rollout of VELSIPITY® through multi-channel access, diversified patient support programs, and innovative reimbursement solutions. And we will work to secure inclusion of VELSIPITY® in the National Reimbursement Drug List, further enhancing patient access and affordability.”

In 2024 and 2025, VELSIPITY® was included in the Catalogues of Guangdong Province on Drugs and Medical Devices from Hong Kong and Macao in Urgent Clinical Use in Nine Mainland Municipalities of the Guangdong-Hong Kong-Macao Greater Bay Area, making it available at designated hospitals across the region. To support long-term supply and commercialization, Everest launched the localized production project for VELSIPITY® at its Jiashan manufacturing site in March 2025, strengthening its supply capabilities for Greater China and other Asian markets.

VELSIPITY® has been strongly recommended as a first-line treatment for moderately to severely active ulcerative colitis in both the American Gastroenterological Association (AGA) Clinical Practice Guideline and the American College of Gastroenterology (ACG) Clinical Guideline Update, reflecting strong recognition of its efficacy and safety by leading international academic societies.

The approval of VELSIPITY® in China was supported by results from the Asian multicenter Phase 3 ENLIGHT UC study (ES101002) and the global ELEVATE UC Phase 3 program (ELEVATE UC 52 and ELEVATE UC 12)6, which demonstrated statistically significant improvements in clinical remission and mucosal healing, along with a favorable safety profile. The ENLIGHT UC study is the largest Phase 3 trial of moderately to severely active UC in Asia completed to date, with 340 eligible subjects randomized to treatment with VELSIPITY® or placebo. The study results showed that, VELSIPITY® demonstrated statistically significant and clinically meaningful improvements across all primary and secondary efficacy endpoints during both the 12-week induction period and the 40-week maintenance period. The safety profile of VELSIPITY® was consistent with previous studies, with no new safety signals observed. ELEVATE UC 52 and ELEVATE UC 12 are randomized, double-blind, placebo-controlled global phase 3 pivotal studies, which further demonstrate the positive benefit-risk profile of VELSIPITY®

References:

  1. K. Wu, et al. Lancet Gastroenterol Hepatol. 2025 Sep 30:S2468-1253(25)00198-0. 
  2. B E Sands, et al. ECCO 2026. Abstract ID: jjaf231.774.
  3. D.T. Rubin, et al. ECCO 2026. Abstract ID: jjaf231.1256.
  4. Shao B, et al. Front Public Health. 2022 Oct 25;10:1032679.    
  5. Kaplan GG. Nat Rev Gastroenterol Hepatol. 2015;12(12):720-727. 
  6. Sandborn WJ, et al. Lancet. 2023 Apr 8;401(10383):1159-1171.

About VELSIPITY® (etrasimod arginine tablets)
VELSIPITY® is a once-daily, oral, sphingosine 1-phosphate (S1P) receptor modulator that selectively binds to S1P receptor subtypes 1, 4, and 5. Regulatory approvals have been granted in US, EU, Canada, Japan, Australia, Singapore, UK, Switzerland, Israel, Turkey, India, Hong Kong SAR, Macao SAR and Mainland China for VELSIPITY® in ulcerative colitis, as well as in additional countries. 

About Everest Medicines
Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company’s therapeutic areas of focus include autoimmune, ophthalmology, critical care, and CKM (cardiovascular, kidney, and metabolic) diseases. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company’s website: www.everestmedicines.com.

Forward-Looking Statements
This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

HEART ON WHEELS 2026 Sees Community Come Together to Raise 33,400 Food Items for Families in Need

  • HEART ON WHEELS 2026 once again brought together automotive convoys, corporate partners, and local communities to contribute 33,400 food items, surpassing its 28,000 target. With this, since its inaugural edition in 2023, the event has raised more than 160,000 food items in total
  • Over the 2-day event, a total of 13 car and motorcycle clubs, together with members of the public, turned up in close to 250 vehicles
  • Beyond the donations, the event seeks to champion the spirit of “neighbourism” in Singapore, bringing together communities, businesses and volunteers to support families facing food insecurity.

SINGAPORE, March 9, 2026 /PRNewswire/ — HEART ON WHEELS 2026, the annual food donation drive-thru organised by Food from the Heart (FFTH) in partnership with Wearnes Automotive, rallied the automotive community, corporate partners, and members of the public across two days of giving at Leng Kee Road.

Mr Eric Chua, Senior Parliamentary Secretary and Member of Parliament for Tanjong Pagar GRC (Queenstown), pictured with representatives from automotive clubs, school students, Food from the Heart volunteers, and members of the public who turned up to donate at Heart on Wheels 2026.
Mr Eric Chua, Senior Parliamentary Secretary and Member of Parliament for Tanjong Pagar GRC (Queenstown), pictured with representatives from automotive clubs, school students, Food from the Heart volunteers, and members of the public who turned up to donate at Heart on Wheels 2026.

Over the course of the weekend on the 7th and 8th March, 13 car and motorcycle clubs, alongside corporate teams and public donors, arrived in around 250 vehicles to contribute 33,400 food items and over $55,000 in cash donations. The contributions will support FFTH’s five food distribution programmes — Community Food Pack, Community Shop, School Goodie Bag, Bread Run and Market Place — helping sustain food aid operations for families, seniors and students in need across Singapore.

The event was officiated by Mr. Eric Chua, Senior Parliamentary Secretary and Member of Parliament for Tanjong Pagar GRC (Queenstown), who arrived with volunteers from Queenstown Grassroots Organisations and 40 students from Bukit Merah Secondary School and Queenstown Secondary School, in vehicles with food donations. Around 100 motorcycles swiftly arrived, further revving up the energy.

Since its inception in 2023, the event has raised over 165,000 food items and close to $235,000 in financial contributions across all four editions, including more than 33,000 food items and nearly $50,000 raised in 2025 alone. With FFTH continuing to expand its food support efforts, HEART ON WHEELS has grown into a community-led movement that reflects a growing spirit of neighbourism in Singapore, bringing together corporates, automotive enthusiasts, and members of the public to support families facing food insecurity.

“What we are seeing through events like HEART ON WHEELS is a growing willingness from communities and businesses to step forward when it matters,” said Robin C. Lee, CEO of Food from the Heart. “For many families and seniors, the rising cost of daily essentials means food support programmes are becoming an important lifeline. Contributions from communities, corporates, and the public help us keep our shelves stocked and ensure that the people who rely on our programmes continue to receive the food they need.”

Automotive and Corporate Partners Rally Community Support

Building on last year’s strong participation, brands under the Wearnes Automotive retailer, including Aston Martin, Bentley, Ducati, Harley-Davidson, Polestar and Volvo, once again rallied their client communities and staff to support the event through food donations, volunteering efforts and participation in the drive-thru donation effort.

Motorcycle communities and car clubs arrived in coordinated convoys throughout the weekend, contributing food donations and encouraging members of the public to take part in the drive-thru collection. The steady stream of vehicles dropping off food items highlighted how enthusiast communities can channel their shared passion into meaningful community support.

Several participating brands also supported the operational side of the event. Volvo, for instance, contributed to last-mile delivery efforts by helping deliver School Goodie Bags to 50 students, extending the impact of the event beyond the donation drive itself. Participating brands also mobilised staff volunteers to assist with on-site activities, including sorting food donations and supporting the drive-thru collection.

Alongside the automotive community, a wide range of organisations organised internal food donation drives and rallied their networks in support of the event. Contributors included Singapore Human Resource Institute, Canopy Hawkers Group, Tong Song Produce, Edrington, Janus Henderson Investors, KBR, Standard Chartered Bank and Thomson Plaza, reflecting strong support from businesses across different sectors.

Corporate support also extended to financial contributions that help sustain Food from the Heart’s food distribution efforts. Key donors included Cargill Cares Singapore and Jacobs, alongside additional contributors such as Kyoho Marketing Pte Ltd and Tiong Bahru Bakery, demonstrating how businesses continue to play an important role in strengthening community-driven food support.

Food from the Heart hopes the event will continue to inspire individuals, businesses and communities to step forward in support of families facing food insecurity. Through collective action and everyday acts of giving, the organisation aims to strengthen a spirit of neighbourism in Singapore, ensuring that no one is left without access to essential food support.

For more information on how to contribute, visit foodfromtheheart.sg or foodfromtheheart.sg/how2026/.

About Food from the Heart
Food from the Heart (FFTH) is an independent, homegrown food charity with IPC status, with a mission to alleviate food insecurity by providing reliable, consistent and sustainable food support to the less-fortunate through food distribution programmes. With the support of donors, food industry partners, and volunteers, FFTH made a difference to the lives of more than 64,000 people throughout Singapore by distributing $8.5 million worth of food in 2024. For more information, please visit foodfromtheheart.sg.

 

AIP Capital Announces Dimuth Fernando as Chief Commercial Officer

STAMFORD, Conn. and SINGAPORE and DUBLIN and NEW YORK, March 9, 2026 /PRNewswire/ — AIP Capital, an alternative investment manager focused on opportunities in asset-based finance today announced that it has promoted Dimuth Fernando to Chief Commercial Officer leading AIP’s global commercial efforts. Dimuth has been with AIP Capital since 2024 as head of AIP’s Singapore office where he led the commercial efforts in the APAC and Central Asia regions.

“We are excited to formally announce Dimuth’s promotion to leading AIP’s commercial efforts to serve regional and global industry clients across the firm’s client base” said Jared Ailstock, Managing Partner at AIP Capital. “Dimuth brings deep experience and a track record in aircraft financing, sales, leasing and partnering with airline customers over more than 20 years.”

Dimuth Fernando commented, “I’m honored to take on the role as Chief Commercial Officer and look forward to serving our valued airline customers worldwide, strengthening our partnerships, and delivering tailored fleet and financing solutions that support their long-term success.”

Prior to joining AIP Capital, Dimuth served as the senior vice president of marketing for global aircraft lessor, Jackson Square Aviation (JSA) where he was responsible for leading origination, sales, remarketing, and airline relationships. Before JSA, he served as the sales director for Embraer, regional jet manufacturer from Brazil. Dimuth started his career with the Boeing Company in aircraft product development and later progressed to senior positions in freighter conversions, supply chain management, aircraft marketing and financing for Middle East and Asia Pacific regions.

About AIP Capital

AIP Capital (AIP) is a global alternative investment manager focused on opportunities in asset-based finance including aviation and equipment finance. AIP, together with its affiliates, manages approximately $6.6 billion of assets on behalf of a diversified global investor base. The AIP team is comprised of ~60 experienced professionals across AIP’s offices in Stamford, New York City, Dublin, Singapore, Seoul & Tokyo.

For more information about AIP Capital or to speak with company executives, please contact investor.relations@aipcapital.com.

Media Contacts
AIP Capital
Geoffrey Bayers
investor.relations@aipcapital.com

Cypherpunk Makes $5M Investment into Zcash Open Development Lab (ZODL)

Cypherpunk expands its holdings with new $5M investment in Zcash company, ZODL, alongside key investors including a16z, Winklevoss Capital, Coinbase, Paradigm, Chapter One, David Friedberg, Balaji Srinivasan, and others

CAMBRIDGE, Mass., March 9, 2026 /PRNewswire/ — Cypherpunk Technologies Inc., (Nasdaq: CYPH) today announced the company has invested $5M into Zcash Open Development Lab (ZODL) marking its first technology investment outside of ZEC. ZODL was founded and is led by former Electric Coin Company (ECC) CEO Josh Swihart.

At ECC, Josh and his team, who have joined him at ZODL, launched the top Zcash wallet, Zashi, now rebranded to Zodl. Zashi was arguably the single biggest factor responsible for putting Zcash back on the map last year. In particular, its simple UX allowed for the Orchard shielded pool to grow from ~1M ZEC to ~4M ZEC during the span of 2025.

ZODL, which now houses the Zashi wallet technology and related intellectual property, aims to make Zcash easier to use with continued development of the wallet, as well as supporting Zcash at the protocol level.

The new investment strongly aligns with Cypherpunk’s mission of advancing technologies that guarantee privacy for all humans on the internet and gives its shareholders exposure to a private company building critical privacy infrastructure on the frontier.

“True to their name, Cypherpunk is backing the builders who will put shielded ZEC in the hands of billions. We’re grateful for their support and proud to partner with them in bringing private digital money to the global mainstream.” – Josh Swihart, CEO of ZODL

The investment in ZODL is highly synergistic with Cypherpunk’s ZEC treasury.

“As ZODL makes Zcash easier to use, we expect adoption of the protocol to grow alongside demand for ZEC.” – Cameron and Tyler Winklevoss

Swihart joined Cypherpunk in December as a strategic advisor. Cypherpunk’s current total ZEC holdings stand at 294,743.10, at an average price of $335.89, bringing the company’s total network ownership to ~1.78%.

“ZODL and Cypherpunk are the two most important companies in privacy. We’re excited to embark together on this mission of accelerating technology that defends self-sovereignty and secures human freedom.” Will McEvoy, Chief Investment Officer of Cypherpunk

About Cypherpunk

Cypherpunk Technologies Inc. is a privacy technology company implementing a digital asset treasury strategy anchored by Zcash and, through its subsidiary Leap Therapeutics, Inc., is developing novel therapies for patients with cancer. The Company is aiming to build long-term shareholder value by acquiring ZEC, participating in the development of privacy technologies and Zcash, and continuing the development of sirexatamab and FL-501 to treat patients with cancer. For more information about the Company, visit our websites at http://www.cypherpunk.com and http://www.leaptx.com or view our public filings with the SEC that are available via EDGAR at http://www.sec.gov or via https://investors.leaptx.com/.

About Winklevoss Capital

Winklevoss Capital is an investment firm founded in 2012 by Cameron and Tyler Winklevoss that invests in frontier technologies.

FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements generally can be identified by the use of words such as “anticipate,” “expect,” “plan,” “could,” “may,” “will,” “believe,” “estimate,” “forecast,” “goal,” “project,” and other words of similar meaning. Forward-looking statements address various matters including statements relating to the investment in Zcash Open Development Lab (“ZODL”), ZEC, or digital assets held or to be held by the Company, the expected future market, price and liquidity of ZEC or other digital assets the Company acquires, the macro and political conditions surrounding Zcash or digital assets, the Company’s plan for value creation and strategic advantages, market size and growth opportunities, regulatory conditions, competitive position and the interest of other corporations in similar business strategies, technological and market trends, and future financial condition and performance. Risks and uncertainties of the digital asset treasury strategy include, among others: (a) the risk that the Company will fail to realize the anticipated benefits of the investment in ZODL and the digital asset treasury strategy; (b) changes in business, market, financial, political and regulatory conditions; (c) risks relating to the Company’s operations and business, including the highly volatile nature of the price of cryptocurrencies, including ZEC; (d) the risk that the price of the Company’s Common Stock may be highly correlated to the price of ZEC or other digital assets that it holds; (e) risks related to increased competition in the industries in which the Company does and will operate; (f) risks relating to significant legal, commercial, regulatory and technical uncertainty regarding digital assets generally; and (g) risks relating to the treatment of crypto assets for U.S. and foreign tax purposes. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements. The Company may not actually achieve the forecasts disclosed in such forward-looking statements, and you should not place undue reliance on such forward-looking statements. Such forward-looking statements are subject to a number of material risks and uncertainties including but not limited to those set forth under the caption “Risk Factors” in the Company’s most recent Annual Report on Form 10-K filed with the SEC, or as may be included in other reports or information we file with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in its subsequent filings with the SEC. Any forward-looking statement speaks only as of the date on which it was made. Neither the Company, nor any of its affiliates, advisors or representatives, undertake any obligation to publicly update or revise any forward-looking statement, whether as a result of new information, future events or otherwise, except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

CONTACT:

Douglas E. Onsi
President & Chief Executive Officer
Cypherpunk Technologies Inc.
617-714-0360
ir@cypherpunk.com 

For Media:
Jacqueline Ortiz Ramsay
It Factor Strategies
954-294-3249
jacqueline@itfactorstrategies.com 

For Investors:
Matthew DeYoung
Investor Relations
Argot Partners
212-600-1902
leap@argotpartners.com